Phase Ib/II Platform Study of Multiple Anti-Cancer Agents in Participants With Metastatic Prostate Cancer

Trial Details

NCT ID

NCT07590934

Phase

PHASE1 / PHASE2

Sponsor

AstraZeneca

Status

RECRUITING

Cancer Type

Prostate Cancer

Interventions

• AZD2265 (FPI-2265)
• Palacaparib (AZD9574)
• Docetaxel
• AZD2287 (Imaging agent)

Locations (sample)

• Duarte, California, United States|34.13945,-117.97729
• Encino, California, United States|34.15917,-118.50119
• South Pasadena, California, United States|34.11612,-118.15035
• Miami, Florida, United States|25.77427,-80.19366
• Orlando, Florida, United States|28.53834,-81.37924

Key Eligibility Criteria

• Participants with a diagnosis of histologically confirmed adenocarcinoma of the prostate (no small cell, neuroendocrine, sarcomatoid, spindle or si…
• Minimum life expectancy of 3 months or more.
• Eastern Cooperative Oncology Group (ECOG) performance status of O or 1 at screening, with no deterioration.
• PCWG3 (Prostate Cancer Working Group 3) modified RECIST Version 1.1 evaluable disease.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.